Increased levels of granulocyte macrophage colony stimulating factor in hypercholesterolemic patients

Parissis, John; Venetsanou, Koula; Kalantzi, Maria; Mentzikof, D.; Ziras, N.; Merkouris, K.; Gikopoulos, M.; Georgopoulou, Maria; Karas, S.

doi:10.1016/s0021-9150(99)80459-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A novel mediator leading to the transition from compensated to the decompensated state of the syndrome is the activation of a new class of biologically active molecules termed pro-inflammatory cytokines [1,3,4,40]. Pro-inflammatory cytokines (TNF-α, IL-6 and IL-1) and other cytokine-related inflammatory factors are capable of modulating cardiac, muscular and vascular functions, by a variety of mechanisms including activation of tissue and circulating monocytes, production of oxygen free radicals and apoptosis [4,41,42].…”

Section: Anti-inflammatory and Anti-apoptotic Effects Of Levosimendanmentioning

confidence: 99%

Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart

Ia¹,

Jt²,

2005

CMCCHA

View full text Add to dashboard Cite

Recent experimental and clinical observations indicate that over-expression of pro-inflammatory cytokines is actively implicated to chronic heart failure progression through their cytotoxic and negative inotropic effects. Calcium-sensitizing agents, such as levosimendan, promotes inotropy by stabilizing troponin C in a configuration that enhances the calcium sensitivity of cardiac myofilaments, preserving also diastolic relaxation. Levosimendan also opens ATP-dependent potassium channels in peripheral vessels, leading to vasodilatation. Large scale randomized clinical trials have shown that levosimendan administration in patients with severe heart failure due to left ventricular systolic dysfunction results in favorable hemodynamic changes, symptomatic benefit, and a reduction in short-term morbidity and mortality. This review describes current knowledge about novel cellular mechanisms associated with beneficial effects of levosimendan on cardiac contractile performance, focusing mainly on its immunomodulatory and anti-apoptotic properties. Levosimendan-induced improvement in contractile reserve and clinical status of severe heart failure patients, seems to be related with the reduction of major pro-inflammatory cytokines (TNF-alpha, IL-6) and soluble apoptosis signaling molecules Fas/Fas Ligand. Modulation of pro-inflammatory and pro-apoptotic pathways into the failing heart by levosimendan may be an additional pathophysiologic mechanism that prevents further clinical and hemodynamic consequences of abnormal immune responses in decompensated heart failure and beneficially affects the progression of the syndrome.

show abstract

Section: Anti-inflammatory and Anti-apoptotic Effects Of Levosimendanmentioning

confidence: 99%

Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart

Ia¹,

Jt²,

2005

CMCCHA

View full text Add to dashboard Cite

show abstract

Increased levels of granulocyte macrophage colony stimulating factor in hypercholesterolemic patients

Cited by 1 publication

References 0 publications

Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart

Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart

Contact Info

Product

Resources

About